Novartis agrees $3bn deal to buy heart drug biotech from Blackstone
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019
Full Article
Novartis agrees $3bn deal to buy heart drug biotech from Blackstone
FT.com
0 shares
1 views